Brief: AC Immune Reports Positive Interim Results From Phase 2 Trial Of ACI-7104.056
14/11/2024 12:29
Nov 14 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE REPORTS POSITIVE INTERIM RESULTS FROM PHASE 2
TRIAL OF
ACI-7104.056 ACTIVE IMMUNOTHERAPY IN EARLY PARKINSON’S DISEASE
* AC IMMUNE SA - ACI-7104.056 WELL TOLERATED WITH NO
CLINICALLY
RELEVANT SAFETY ISSUES
* AC IMMUNE SA - 100% OF PATIENTS RESPOND TO ACI-7104.056
* AC IMMUNE SA - MAY INITIATE PART 2 OF VACSYN WITH UP TO
150
PATIENTS
Source text: urn:newsml:reuters.com:*:nGNX9sbKKq
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health